Cristina Papayannidis

20PUBLICATIONS
133CO-AUTHORS
Immunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 25, 2026
Real-Life Study on Gilteritinib-Related Infections (GilteRInf): An Italian SEIFEM Study.

|Feb 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Jan 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Calogero Vetro, Irene Azzali, Elisabetta Petracci

|Dec 05, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Aug 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience.

Roberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo

|May 07, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.

Martha L Arellano, Michael J Thirman, John F DiPersio

Pageof 4

Frequent Collaborators

8 joint publications

Giovanni Marconi

5 joint publications

Pau Montesinos

4 joint publications

Adriano Venditti

4 joint publications

Fabio Guolo